help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mäkitie, O.
Right arrow Articles by Sochett, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mäkitie, O.
Right arrow Articles by Sochett, E.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 8 3591-3597
Copyright © 2003 by The Endocrine Society

Early Treatment Improves Growth and Biochemical and Radiographic Outcome in X-Linked Hypophosphatemic Rickets

O. Mäkitie, A. Doria, S. W. Kooh, W. G. Cole, A. Daneman and E. Sochett

Division of Endocrinology (O.M., S.W.K., E.S.), Diagnostic Imaging (A.Do., A.Da.), and Orthopedic Surgery (W.G.C.), The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada M5G 1X8

Address all correspondence and requests for reprints to: Outi Mäkitie, M.D., Ph.D., Division of Endocrinology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. E-mail: outi.makitie{at}helsinki.fi.

X-Linked hypophosphatemic rickets (XLH) is characterized by hypophosphatemia, rickets, and impaired growth. Despite oral phosphate and 1,25-dihydroxyvitamin D3 treatment, many patients have suboptimal growth and bone healing. The aim of this study was to assess whether age at treatment onset impacts the outcome. Growth data, biochemistry, and radiographs of 19 well-controlled patients with XLH were analyzed retrospectively. Patients were divided into two groups based on the age at treatment onset (group 1, <1.0 yr; group 2, >=1.0 yr). The median height z-score was higher in group 1 (n = 8) than in group 2 (n = 11) at treatment onset [-0.4 SD score (SDS) vs. -1.7 SDS; P = 0.001], at the end of the first treatment year (-0.7 SDS vs. -1.8 SDS; P = 0.009), throughout childhood (P > 0.05) and until predicted adult height (-0.2 SDS vs. -1.2 SDS; P = 0.06). The degree of hypophosphatemia was similar in both groups, but serum alkaline phosphatase remained higher in group 2 throughout childhood. Radiographic signs of rickets were more marked in group 2, but even patients with early treatment developed significant skeletal changes of rickets. These data suggest that treatment commenced in early infancy results in improved outcome in patients with XLH, but does not completely normalize skeletal development.

This work was supported by the Foundation for Pediatric Research, the Paulo Foundation, the Jalmari and Rauha Ahokas Foundation, the Maritza and Reino Salonen Foundation, and an ESPE Research Fellowship, sponsored by Novo Nordisk A/S.

Abbreviations: ALP, Alkaline phosphatase; 1,25-(OH)2D3, 1,25-dihydroxyvitamin D3; PAH, predicted adult height; Pi, phosphate; S-, serum level; SDS, SD score; XLH, X-linked hypophosphatemic rickets.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
F. Jehan, C. Gaucher, T. M. Nguyen, O. Walrant-Debray, N. Lahlou, C. Sinding, M. Dechaux, and M. Garabedian
Vitamin D Receptor Genotype in Hypophosphatemic Rickets as a Predictor of Growth and Response to Treatment
J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4672 - 4682.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
U. S. Alon, R. Levy-Olomucki, W. V. Moore, J. Stubbs, S. Liu, and L. D. Quarles
Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 658 - 664.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Makras, N. A. T. Hamdy, S. G. Kant, and S. E. Papapoulos
Normal Growth and Muscle Dysfunction in X-Linked Hypophosphatemic Rickets Associated with a Novel Mutation in the PHEX Gene
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1386 - 1389.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. M. Brunelli and S. Goldfarb
Hypophosphatemia: Clinical Consequences and Management
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 1999 - 2003.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
S. Ferrari
Single Gene Mutations and Variations Affecting Bone Turnover and Strength: a Selective 2006 Update
IBMS BoneKEy, December 1, 2006; 3(12): 11 - 29.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society